Chapter 1844: Chapter 1290: Different anings (Part 2)
“He made it through,” John Ansen exhaled deeply.
Yang Ping nodded, but there was no joy on his face, only calmness. “The immune storm might still have aftereffects, and this is just the beginning.”
According to the agreent, all treatnt data is transmitted in real-ti to the United States NIH server. However, before transmission, the data must undergo a layer of “de-sensitization”—removing patients’ personal identity information but retaining complete treatnt paraters and efficacy data.
“They are requesting the gene sequence of the viral vector,” Song Zimo reported to Yang Ping, “citing the need for safety assessnt.”
“Give them a truncated version,” Yang Ping replied without looking up, “show the vector frawork and targeting parts but hide the core gene editing elents and promoter design.”
Yang Ping explained, “The agreent only ntions sharing ‘treatnt-related data,’ not ‘technical core details.’ We treat patients; they learn the technology—this is an unspoken exchange. But we can’t lay all our cards on the table; controlling core technology is the bottom line. Don’t trust them.”
Song Zimo nodded, beginning to prepare the data package.
anwhile, at the Nandu Ruixing Headquarters, Huang Jiacai was in a new round of talks with representatives of the six giants. This ti, the atmosphere was completely different.
“You’ve all seen the real-ti briefings on Li Gaoyang’s treatnt progress,” Huang Jiacai got straight to the point. “The patient survived the most dangerous immune storm, which ans the K Therapy is also effective for the most critical patients.”
In the eting room, multinational giant representatives exchanged glances. Over the past few days, they had obtained fragnted information about the treatnt process through their channels, but the briefing provided by Huang Jiacai was the most complete.
“The efficacy data is impressive,” Schneider admitted, “but we’ve also noticed serious adverse reactions during the treatnt. Will this affect regulatory approval?”
“Any innovative therapy carries risks,” Huang Jiacai replied. “The key is the risk-benefit ratio. For late-stage patients with only a few months of expected survival, these risks are negligible compared to the benefits.”
He presented a chart, “This is a predictive model updated with Li Gaoyang’s treatnt data. If we initiate formal multi-center clinical trials within three months, we expect K Therapy to receive conditional approval in major global markets by the end of next year. Then, the annual treatnt capacity could reach 50,000 cases, breaking through 500,000 cases in three years.”
Numbers danced on the screen, and the representatives began calculating—500,000 cases, even under a step-by-step pricing frawork, would lead to an annual market size exceeding 10 billion dollars. More importantly, it would completely change the market dynamics of brain tumor treatnt.
“So,” Huang Jiacai glanced around, “the question now is: do you want to be participants in this future or spectators?”
This ti, there was no united front, no common stance. Japan’s Sato was the first to speak: “We are willing to be one of the first partners, responsible for the production landing in Japan. We have prepared a detailed plan that can reduce production costs by over 25%.”
Germany’s Schneider followed closely, “We have the most complete network of doctors in Europe and can train more than a thousand doctors in K Therapy patient screening and managent processes within six months.”
The United States’ Thompson hesitated for a mont but ultimately said, “If the FDA initiates formal approval after Li Gaoyang’s case, we are willing to undertake the North Arican clinical trial organization work with BG.”
One by one, the six giants declared their stance.
The inclusive frawork, which was collectively resisted a month ago, has now beco an unavoidable reality. Li Gaoyang’s treatnt was like a touchstone and a live advertisent, proving the effectiveness of the technology and demonstrating China’s technical control—they rely on no one, thus they can set their own rules.
At the end of the eting, Huang Jiacai announced, “Next week, Ruixing will officially launch the recruitnt of global partners. All applicants will be evaluated according to uniform standards, and the first batch of partner lists will be released within three months. anwhile, we will announce the detailed implentation rules of the inclusive frawork, including pricing formulas, data-sharing chanisms, and quality managent systems.”
The representatives left with complex expressions. They knew they were witnessing the beginning of a new era—in this era, technology leaders are no longer just suppliers but rule-makers; traditional giants must learn to compete under new rules.
A week later, Li Gaoyang began the second phase of K Therapy.
This ti, the process was much smoother. His immune system had already undergone the first “training,” making responses more controllable. Forty-eight hours after treatnt, imaging examinations showed a 15% reduction in tumor size.
Rolf stood in the observation room, looking at Li Gaoyang in the monitoring room, his face no longer ashen like when he first arrived, and there was a spark in his eyes. Yesterday, he even expressed a desire to see the view outside the window.
“Professor Yang,” Rolf found Yang Ping after the eting, “if the treatnt succeeds… can he return to how he was before?”
Yang Ping thought for a mont and answered honestly, “The neurological damage caused by the tumor is irreversible. Even if the tumor completely disappears, he may still have so functional impairnts, which are unavoidable. So, this treatnt also has its golden window, but from our current volunteer treatnts, the chances of leaving lingering effects are not high, and even if there are, they would be relatively mild.”
Rolf was silent for a mont and then said, “That’s enough. As long as he’s alive, there’s hope.”
That night, Huang Jiacai ca to the hospital. He didn’t enter the ward but just looked at Li Gaoyang through the glass, then chatted with Yang Ping.
“The pressure from the United States is great,” Huang Jiacai said. “The White House hopes we will initiate formal multi-center clinical trials as soon as possible. They want to accumulate more data dostically before Europe and Japan.”
“The technical preparation is fine,” Yang Ping said, “but we must control the pace. If we push too fast, quality control may beco an issue. K Therapy is not an assembly line production; each case is customized treatnt.”
“I understand,” Huang Jiacai nodded. “So the condition I talked to them about is: we can speed up, but they must accept our training system and quality control standards. Moreover, the first hundred cases must be completed under our supervision.”
“Exactly, we must insist on our principles.”
“Li Gaoyang’s success leaves them with little choice. That’s the advantage of technology: when you have sothing others don’t, you have the right to set the rules.”
“Professor Yang,” Huang Jiacai suddenly said, “sotis I wonder, are we moving too fast? Challenging the entire global pharmaceutical system’s vested interest structure with one technology.”
Yang Ping turned his head, looking at Huang Jiacai, “Have you seen late-stage tumor patients? I’ve seen too many. So are in their teens, so have just beco parents, and so are top scientists, artists, entrepreneurs. In the face of disease, they are all equal—equally desperate, equally awaiting death.”
He paused for a mont, “If we have the technology to save them but delay because of comrcial interests, political calculations, or so-called ‘industry rules,’ then what difference is there between us and those we once criticized?”
Huang Jiacai didn’t respond imdiately. After a long ti, he finally said, “You’re right. So we must keep walking this path, no matter how difficult it may be.”
Downstairs, in the monitoring room, Li Gaoyang lay with his eyes open, staring at the ceiling. The monitor beeped rhythmically—the sound of life. He thought of many things: studying in his youth, battling competitors after starting work, the euphoria of being appointed BG’s president for the first ti, and the doctor’s calm yet cruel verdict on the day of diagnosis.
Then he rembered what Yang Ping had said to him before the treatnt, “This treatnt will be a bit difficult, but if you can get through it, you’ll discover a different aning to life.”
A different aning… What was it?
He didn’t know the answer yet. But at least, he still had the chance to find out.
User Comments
0 comments from readers